Receive reproducible, regulatory-ready genomic data across every phase of therapeutic development.
CellCarta’s sequencing platforms span the full genomic pipeline, from targeted mutation analysis and bulk transcriptomics to single-cell multi-omics and spatial biology.
Every sequencing workflow is supported by our in-house scientists and a dedicated bioinformatics team, so results move seamlessly from analysis to interpretation without delaying timelines and research progress.
We have access to a vast suite of next-generation sequencing (NGS) platforms that can be tailored to your program’s specifications, including NovaSeq X Plus, NovaSeq 6000, NextSeq550Dx, MiSeqDx.
For single-cell sequencing, we utilize the 10X Genomics Chromium X platform. This platform integrates whole transcriptome RNA sequencing with immune profiling and proteomics analysis for an in-depth cellular insight.
For programs that require a deeper understanding of cells within their environmental context, we have a range of spatial biology platforms available for use. These include:
Our sequencing platforms can run a wide suite of solid tissue and liquid biopsy panels. We have validated several commercial panels for clinical use, including:
Our platforms can accommodate custom panels. Contact our team for further information.
We have access to a vast suite of next-generation sequencing (NGS) platforms that can be tailored to your program’s specifications, including NovaSeq X Plus, NovaSeq 6000, NextSeq550Dx, MiSeqDx.
For single-cell sequencing, we utilize the 10X Genomics Chromium X platform. This platform integrates whole transcriptome RNA sequencing with immune profiling and proteomics analysis for an in-depth cellular insight.
For programs that require a deeper understanding of cells within their environmental context, we have a range of spatial biology platforms available for use. These include:
Our sequencing platforms can run a wide suite of solid tissue and liquid biopsy panels. We have validated several commercial panels for clinical use, including:
Our platforms can accommodate custom panels. Contact our team for further information.
CellCarta offers the NanoString nCounter platform that directly assesses over 800 RNA targets per sample without amplification. This highly reproducible assay delivers accurate gene expression data from limited clinical samples to generate gene signatures and validate gene sets identified from sequencing.
CellCarta developed a workflow that combines Olink Reveal with 10x Genomics single-cell transcriptomics to functionally characterize antigen-specific T cell responses. Generating over 1,034 protein readouts per sample, this approach supports predictive biomarker strategies for clinical trials.
Advanced sequencing platform suite for quality genomics research.
Cross-Validated Platforms
Technology Agnostic
Liquid Biopsy Integration
Dedicated Support
Multi-Modal Capabilities
Explore the sequencing and genomic analysis services most frequently used in translational and clinical biomarker programs.
Precise, high-throughput analysis of genetic material with both speed and scalability.
Cutting-edge technology to understand the transcriptome and its biological context.
High-resolution, scalable, multi-omic approaches to uncover valuable cellular insight.
Case Studies
Blog
Oncology
CellCarta’s sequencing platforms include NovaSeq X Plus, NovaSeq 6000, NextSeq 550Dx, and MiSeqDx. For single-cell RNA sequencing, CellCarta is a certified 10x Genomics service provider and member of their Global CRO program.
Our spatial biology applications are supported by 10x Genomics Visium and Visium HD, NanoString GeoMx Digital Spatial Profiler (DSP), and Lunaphore COMET™. All instruments are cross-validated across our global sites to ensure consistent, comparable outputs regardless of where samples are processed.
Yes. CellCarta operates harmonized genomics laboratories in Naperville (USA), Antwerp (Belgium), and Jining (China). Instruments and processes are cross-validated across sites, so programs that span multiple regions or require regulatory submissions in different jurisdictions receive consistent, comparable data.
